Targeting HIF-2 α in clear cell renal cell carcinoma: A promising therapeutic strategy

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Loss of the Von Hippel-Lindau tumor suppressor (VHL) is a critical event in clear cell renal cell carcinoma (ccRCC) pathogenesis.
• VHL loss leads to the accumulation of hypoxia-inducible factor alpha (HIF-α), which drives tumor adaptation to hypoxia.
• The HIF-2α subunit plays a particularly significant role in ccRCC development compared to HIF-1α.

Purpose of the Study:

• To summarize the molecular rationale for targeting HIF-2α in ccRCC.
• To provide an overview of novel HIF-2α inhibitors in ccRCC treatment development.
• To highlight the therapeutic potential of targeting the HIF-2α pathway in ccRCC.

Main Methods:

• Review of preclinical and clinical data for HIF-2α inhibitors.
• Focus on small molecule inhibitors that disrupt HIF-2α/HIF-1β heterodimerization.
• Analysis of the efficacy of HIF-2α inhibitors in blocking cancer cell growth and angiogenesis.

Main Results:

• PT2385 and PT2399 are first-in-class, orally available HIF-2 inhibitors.
• These inhibitors selectively disrupt HIF-2α/HIF-1β heterodimerization.
• Preclinical and clinical data demonstrate effectiveness in inhibiting ccRCC cell growth, proliferation, and angiogenesis.

Conclusions:

• HIF-2α specific antagonists represent a promising therapeutic strategy for ccRCC.
• Combination therapies involving HIF-2α inhibitors with immunotherapy or antiangiogenic agents may transform ccRCC treatment.
• Targeting HIF-2α offers a novel approach to managing ccRCC by addressing key oncogenic drivers.